Clinical trial / 2015
Omega-3 and lutein/zeaxanthin supplements did not improve cognitive function in older adults.
In an ancillary trial within AREDS2, 3,501 older adults at risk for late age-related macular degeneration were randomized to receive omega-3 polyunsaturated fatty acids, lutein/zeaxanthin, both, or placebo. Over five years, yearly change in composite cognitive test scores did not differ between the fatty acid group (-0.19; 99% CI, -0.25 to -0.13) and control (-0.18; 99% CI, -0.24 to -0.12; P = .63). Similarly, lutein/zeaxanthin showed no difference compared to placebo (P = .66).
- Study type
- Randomized controlled trial
- Who was studied
- 3,501 older adults with AMD risk (mean age 72.7 years, 57.5% women), United States
- What was measured
- Yearly change in composite cognitive function score
THE PAPER
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.
Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, Age-Related Eye Disease Study 2 (AREDS2) Research Group. JAMA, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.